ClinicalTrials.gg
CompletedNCT06901284Updated Oct 14, 2026

Graded Exercise Hypoxia Testing

An observational study in Hypoxia, sponsored by Mayo Clinic. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Mayo Clinic · Observational

How we know

Updated Oct 14, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 269 studies in Hypoxia with a site in United States — 36 open to participants now, 51 under way, 2 of them phase 3. Hypoxia · United States.

Enrollment
43rd of 87
30 · median 30
Started
2025
with 15 others
Observational
87 of 269
13 open now
Registered
249th of 269
by date

Among the 269 studies in Hypoxia with a site in United States, this one is the 43rd largest by enrollment of the 87 observational ones that give a count, is one of 16 that started in 2025, is one of 87 observational ones, and was the 249th registered.

Hypoxia

1,081 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

Browse Hypoxia studies →

Open to participants now

36 of the 269 studies in Hypoxia with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Hypoxia studies recruiting now, 52 (42%) set no upper age limit and 46 (37%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 269 studies in Hypoxia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to develop a single, standardized test to determine how individuals tolerate acute hypoxia in a stepwise fashion. We aim to evaluate the association between multiple factors, such as ventilatory compensation, heart rate response, acid-base changes, sex, pulmonary function, etc, which may explain why some individuals tolerate exercise in hypoxia better than others. Identifying these factors of association will inform future pharmacological and non-pharmacological attempts to combat acute hypoxic exercise.

03

Conditions studied

  • Hypoxia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

A total of 50 participants (25 female, 25 male) will be recruited for this study. Participants will be recruited from the general population.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physically active (≥150 minutes of moderate physical activity per week)

Exclusion criteria

Exclusion Criteria:

  • to exercise testing
  • Currently pregnant
  • Musculoskeletal or metabolic disease
  • Allergies to lidocaine
  • Body-mass index ≤18 or ≥35 kg·m-2
  • Pacemaker
  • No confounding cardiorespiratory disease
  • Persistent tobacco use (>15 pack years)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • Study group

    50 participants (25 female, 25 male) who are physically active for at least 150 minutes per week, at a moderate activity level.

    Diagnostic Test: Graded Exercise Test · Diagnostic Test: Graded Hypoxia Exercise Test

Interventions

  • Diagnostic testGraded Exercise Test

    Participants will perform a graded exercise test on either a cycle ergometer or treadmill. The testing protocol will begin with a 5- 10 min warm-up of either cycling or running/walking at the participants preferred pace. If the graded exercise test is on a bike, exercise will begin at wattage that elicits \~50% of their heart rate max, HRmax = 208 - 0.7 × age and increase by either 10W, 15W, or 20W every two minutes in a stepwise fashion until symptom limitation. The step of the wattage increase will be at the discretion of the investigators. If the graded exercise test is on a treadmill, the test will begin at a speed that elicits \~50% of predicted HRmax. Following, the speed of the treadmill will increase 0.5 mph (0.8 km/hr) every two minutes in a stepwise fashion until symptom limitation. If the participant maxes out the speed of the treadmill, we will increase the grade 2% every 2-minutes until symptom limitation.

  • Diagnostic testGraded Hypoxia Exercise Test

    Participants will perform a single constant work rate exercise tests during graded hypoxia. They will be outfitted with either a facemask or mouthpiece connected to a uni-directional breathing valve. During inspiration, subjects will breathe from a closed-system Douglas bag balloon reservoir (\~200 L) connected to the value on the inspired side via air-tight clean-bor tubing. The participant will complete the same mode of exercise as they did during visit 1, either bike or treadmill. The resistance on the bike or incline of the treadmill will be set to elicit an intensity equivalent to \~50% of their V̇O2max determined during visit 1. Participants will complete 5-minute stages over a range of FiO2 values. The exercise test will begin in an FiO2=0.21 (i.e. room air). Following this first 5-min stage the FiO2 will increase to 0.25, afterwards, participants will complete another stage at FiO2=0.21 and then decrease in a stepwise fashion every 5-minutes.

06

What researchers measure

Primary outcomes

  1. PaO₂/FiO₂ Ratio

    The PaO₂/FiO₂ ratio is a widely used measure of oxygenation efficiency in the lungs. It compares the arterial oxygen partial pressure (PaO₂, measured in mmHg) to the fraction of inspired oxygen (FiO₂, expressed as a decimal). The ratio provides insight into the ability of the lungs to transfer oxygen into the bloodstream. A PaO₂/FiO₂ ratio of 300-400 is considered to be mild hypoxemia. Participants are considered as poorly tolerating hypoxia if their ratio is \<400 and good at tolerating hypoxia if their ratio is \>400.

    Time frame: 30 minutes

07

Study locations

2 sites
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • St. Mary's Hospital
    Rochester, Minnesota 55902, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2025 to primary completion in Jul 2025, 3 months.

Of 125 non-industry observational studies under Hypoxia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 74. This study's 3 months is below that.

Counting every sponsor, half of 155 studies reached it within 14 months; a quarter within 3 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Apr 2027 → Jul 2025 and completion Apr 2028 → Sep 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Mar 28, 2025
StartActual
Apr 15, 2025
Primary completionActual
Jul 30, 2025was Apr 2027
CompletionActual
Sep 11, 2025was Apr 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 14, 2026
Primary completion
Apr 24, 2027→Jul 30, 2025 (actual)
Oct 14, 2026
Study completion
Apr 24, 2028→Sep 11, 2025 (actual)
Oct 14, 2026
Enrollment
50 (estimated)→30 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Active, not recruiting→Completed
    Primary completion Apr 24, 2027→Jul 30, 2025 (now actual)
    Study completion Apr 24, 2028→Sep 11, 2025 (now actual)
    Enrollment 50 (estimated)→30 (actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06901284
Lead sponsor
Mayo Clinic
Responsible party
Michael J. Joyner, M.D. (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Mar 28, 2025
Start date
Apr 15, 2025
Primary completion
Jul 30, 2025
Completion
Sep 11, 2025
Last update
Oct 14, 2026

Study contacts

Michael Joyner, M.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion